S&P 500   3,091.71 (-0.08%)
DOW   27,743.95 (-0.14%)
QQQ   201.09 (-0.25%)
CGC   15.58 (-15.78%)
BABA   181.93 (-0.30%)
T   38.76 (-1.02%)
F   8.80 (-0.11%)
PRI   129.13 (+0.41%)
BAC   32.57 (-0.67%)
DIS   147.91 (-0.54%)
S&P 500   3,091.71 (-0.08%)
DOW   27,743.95 (-0.14%)
QQQ   201.09 (-0.25%)
CGC   15.58 (-15.78%)
BABA   181.93 (-0.30%)
T   38.76 (-1.02%)
F   8.80 (-0.11%)
PRI   129.13 (+0.41%)
BAC   32.57 (-0.67%)
DIS   147.91 (-0.54%)
S&P 500   3,091.71 (-0.08%)
DOW   27,743.95 (-0.14%)
QQQ   201.09 (-0.25%)
CGC   15.58 (-15.78%)
BABA   181.93 (-0.30%)
T   38.76 (-1.02%)
F   8.80 (-0.11%)
PRI   129.13 (+0.41%)
BAC   32.57 (-0.67%)
DIS   147.91 (-0.54%)
S&P 500   3,091.71 (-0.08%)
DOW   27,743.95 (-0.14%)
QQQ   201.09 (-0.25%)
CGC   15.58 (-15.78%)
BABA   181.93 (-0.30%)
T   38.76 (-1.02%)
F   8.80 (-0.11%)
PRI   129.13 (+0.41%)
BAC   32.57 (-0.67%)
DIS   147.91 (-0.54%)
Log in

Generex Biotechnology Stock Price, Forecast & Analysis (OTCMKTS:GNBT)

$0.95
-0.13 (-12.04 %)
(As of 11/14/2019 08:51 AM ET)
Today's Range
$0.94
Now: $0.95
$1.10
50-Day Range
$1.08
MA: $1.84
$2.58
52-Week Range
$0.28
Now: $0.95
$1.64
Volume318,191 shs
Average Volume147,160 shs
Market Capitalization$61.13 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.99
Generex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices. The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:GNBT
CUSIPN/A
Phone416-364-2551

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$700,000.00
Book Value($1.94) per share

Profitability

Miscellaneous

Employees3
Market Cap$61.13 million
Next Earnings DateN/A
OptionableNot Optionable

Receive GNBT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNBT and its competitors with MarketBeat's FREE daily newsletter.


Generex Biotechnology (OTCMKTS:GNBT) Frequently Asked Questions

What is Generex Biotechnology's stock symbol?

Generex Biotechnology trades on the OTCMKTS under the ticker symbol "GNBT."

Has Generex Biotechnology been receiving favorable news coverage?

Headlines about GNBT stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Generex Biotechnology earned a coverage optimism score of -1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Generex Biotechnology.

Who are some of Generex Biotechnology's key competitors?

What other stocks do shareholders of Generex Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Generex Biotechnology investors own include SLS International (SLS), Unilife (UNISQ), Amgen (AMGN), Snap (SNAP), Novavax (NVAX), United States Steel (X), Avid Bioservices (CDMO), Ceragon Networks (CRNT), Canopy Growth (CGC) and Oracle (ORCL).

Who are Generex Biotechnology's key executives?

Generex Biotechnology's management team includes the folowing people:
  • Mr. Joseph Moscato, Chairman, Pres & CEO (Age 55)
  • Mr. Mark Corrao, CFO & Treasurer (Age 64)
  • Mr. Andrew Ro, Chief Investment Officer & Director (Age 48)
  • Mr. Richard D. Purcell, Sr. VP of Research & Drug Devel. (Age 58)
  • Mr. Terry R. Thompson, Chief Operating Officer (Age 61)

How do I buy shares of Generex Biotechnology?

Shares of GNBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Generex Biotechnology's stock price today?

One share of GNBT stock can currently be purchased for approximately $0.95.

How big of a company is Generex Biotechnology?

Generex Biotechnology has a market capitalization of $61.13 million and generates $700,000.00 in revenue each year. Generex Biotechnology employs 3 workers across the globe.View Additional Information About Generex Biotechnology.

What is Generex Biotechnology's official website?

The official website for Generex Biotechnology is http://www.generex.com/.

How can I contact Generex Biotechnology?

Generex Biotechnology's mailing address is 10102 USA TODAY WAY, MIRAMAR FL, 33025. The company can be reached via phone at 416-364-2551 or via email at [email protected]


MarketBeat Community Rating for Generex Biotechnology (OTCMKTS GNBT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  64 (Vote Underperform)
Total Votes:  154
MarketBeat's community ratings are surveys of what our community members think about Generex Biotechnology and other stocks. Vote "Outperform" if you believe GNBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel